REFERENCES
2. Champoux JJ. Structure-based analysis of the effects of camptothecin on the activities of human topoisomerase I. Ann N Y Acad Sci 2000;922:56-64.
3. Vos SM, Tretter EM, Schmidt BH, Berger JM. All tangled up: how cells direct, manage and exploit topoisomerase function. Nat Rev Mol Cell Biol 2011;12:827-41.
4. Peter BJ, Ullsperger C, Hiasa H, Marians KJ, Cozzarelli NR. The structure of supercoiled intermediates in DNA replication. Cell 1998;94:819-27.
5. Liu LF, Wang JC. Supercoiling of the DNA template during transcription. Proc Natl Acad Sci U S A 1987;84:7024-7.
6. Stewart L, Redinbo MR, Qiu X, Hol WG, Champoux JJ. A model for the mechanism of human topoisomerase I. Science 1998;279:1534-41.
7. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, et al. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc Natl Acad Sci U S A 2002;99:15387-92.
8. Lin CP, Ban Y, Lyu YL, Liu LF. Proteasome-dependent processing of topoisomerase I-DNA adducts into DNA double strand breaks at arrested replication forks. J Biol Chem 2009;284:28084-92.
9. Regairaz M, Zhang YW, Fu H, Agama KK, Tata N, et al. Mus81-mediated DNA cleavage resolves replication forks stalled by topoisomerase I-DNA complexes. J Cell Biol 2011;195:739-49.
10. Sordet O, Redon CE, Guirouilh-Barbat J, Smith S, Solier S, et al. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. EMBO Rep 2009;10:887-93.
11. Cristini A, Ricci G, Britton S, Salimbeni S, Huang SN, et al. Dual processing of R-loops and topoisomerase I induces transcription-dependent DNA double-strand breaks. Cell Rep 2019;28:3167-81.e6.
12. Rowinsky EK. Weekly topotecan: an alternative to topotecan’s standard daily x 5 schedule? Oncologist 2002;7:324-30.
13. Pourquier P, Ueng LM, Fertala J, Wang D, Park HJ, et al. Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine. J Biol Chem 1999;274:8516-23.
14. Daroui P, Desai SD, Li TK, Liu AA, Liu LF. Hydrogen peroxide induces topoisomerase I-mediated DNA damage and cell death. J Biol Chem 2004;279:14587-94.
15. Pourquier P, Jensen AD, Gong SS, Pommier Y, Rogler CE. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Res 1999;27:1919-25.
16. Pourquier P, Ueng LM, Kohlhagen G, Mazumder A, Gupta M, et al. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997;272:7792-6.
17. Pourquier P, Pilon AA, Kohlhagen G, Mazumder A, Sharma A, et al. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps. Importance of DNA end phosphorylation and camptothecin effects. J Biol Chem 1997;272:26441-7.
18. Yeh YC, Liu HF, Ellis CA, Lu AL. Mammalian topoisomerase I has base mismatch nicking activity. J Biol Chem 1994;269:15498-504.
19. Pommier Y, Kohlhagen G, Pourquier P, Sayer JM, Kroth H, et al. Benzo[a]pyrene diol epoxide adducts in DNA are potent suppressors of a normal topoisomerase I cleavage site and powerful inducers of other topoisomerase I cleavages. Proc Natl Acad Sci U S A 2000;97:2040-5.
20. Antony S, Theruvathu JA, Brooks PJ, Lesher DT, Redinbo M, et al. Enhancement of camptothecin-induced topoisomerase I cleavage complexes by the acetaldehyde adduct N2-ethyl-2’-deoxyguanosine. Nucleic Acids Res 2004;32:5685-92.
21. Lesher DT, Pommier Y, Stewart L, Redinbo MR. 8-Oxoguanine rearranges the active site of human topoisomerase I. Proc Natl Acad Sci U S A 2002;99:12102-7.
22. Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 2002;3:415-24.
23. Gmeiner WH, Konerding D, James TL. Effect of cytarabine on the NMR structure of a model okazaki fragment from the SV40 genome. Biochemistry 1999;38:1166-75.
24. Gmeiner WH, Skradis A, Pon RT, Liu J. Cytarabine-induced destabilization of a model Okazaki fragment. Nucleic Acids Res 1998;26:2359-65.
25. Huang SY, Murai J, Dalla Rosa I, Dexheimer TS, Naumova A, et al. TDP1 repairs nuclear and mitochondrial DNA damage induced by chain-terminating anticancer and antiviral nucleoside analogs. Nucleic Acids Res 2013;41:7793-803.
26. Bonven BJ, Gocke E, Westergaard O. A high affinity topoisomerase I binding sequence is clustered at DNAase I hypersensitive sites in Tetrahymena R-chromatin. Cell 1985;41:541-51.
27. Pourquier P, Takebayashi Y, Urasaki Y, Gioffre C, Kohlhagen G, et al. Induction of topoisomerase I cleavage complexes by 1-beta-D-arabinofuranosylcytosine (ara-C) in vitro and in ara-C-treated cells. Proc Natl Acad Sci U S A 2000;97:1885-90.
28. Patel AG, Flatten KS, Peterson KL, Beito TG, Schneider PA, et al. Immunodetection of human topoisomerase I-DNA covalent complexes. Nucleic Acids Res 2016;44:2816-26.
29. Cline SD, Osheroff N. Cytosine arabinoside lesions are position-specific topoisomerase II poisons and stimulate DNA cleavage mediated by the human type II enzymes. J Biol Chem 1999;274:29740-3.
30. Loegering D, Arlander SJ, Hackbarth J, Vroman BT, Roos-Mattjus P, et al. Rad9 protects cells from topoisomerase poison-induced cell death. J Biol Chem 2004;279:18641-7.
31. Sousa FG, Matuo R, Tang SW, Rajapakse VN, Luna A, et al. Alterations of DNA repair genes in the NCI-60 cell lines and their predictive value for anticancer drug activity. DNA Repair (Amst) 2015;28:107-15.
32. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci U S A 2012;109:15030-5.
33. Murai J, Tang SW, Leo E, Baechler SA, Redon CE, et al. SLFN11 Blocks Stressed Replication Forks Independently of ATR. Mol Cell 2018;69:371-84.e6.
34. Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, et al. TDP1 is critical for the repair of DNA breaks induced by sapacitabine, a nucleoside also targeting ATM- and BRCA-deficient tumors. Mol Cancer Ther 2017;16:2543-51.
35. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol 2006;17 Suppl 5:v7-12.
36. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W. Action of 2’,2’-difluorodeoxycytidine on DNA synthesis. Cancer Res 1991;51:6110-7.
37. Konerding D, James TL, Trump E, Soto AM, Marky LA, et al. NMR structure of a gemcitabine-substituted model Okazaki fragment. Biochemistry 2002;41:839-46.
38. Gmeiner WH. Antimetabolite incorporation into DNA: structural and thermodynamic basis for anticancer activity. Biopolymers 2002;65:180-9.
39. Pourquier P, Gioffre C, Kohlhagen G, Urasaki Y, Goldwasser F, et al. Gemcitabine (2’,2’-difluoro-2’-deoxycytidine), an antimetabolite that poisons topoisomerase I. Clin Cancer Res 2002;8:2499-504.
40. An Q, Robins P, Lindahl T, Barnes DE. 5-Fluorouracil incorporated into DNA is excised by the Smug1 DNA glycosylase to reduce drug cytotoxicity. Cancer Res 2007;67:940-5.
41. Ensminger WD, Rosowsky A, Raso V, Levin DC, Glode M, et al. A clinical-pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2’-deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-92.
42. Gmeiner WH. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005;12:191-202.
43. Saif MW, Syrigos K, Mehra R, Mattison LK, Diasio RB. Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies: experience of 4-years. Pak J Med Sci 2007;23:832-9.
44. Dominijanni A, Gmeiner WH. Improved potency of F10 relative to 5-fluorouracil in colorectal cancer cells with p53 mutations. Cancer Drug Resist 2018;1:48-58.
45. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol 2016;12:2009-20.
46. Liao ZY, Sordet O, Zhang HL, Kohlhagen G, Antony S, et al. A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes. Cancer Res 2005;65:4844-51.
47. Gmeiner WH, Reinhold WC, Pommier Y. Genome-wide mRNA and microRNA profiling of the NCI 60 cell-line screen and comparison of FdUMP[10] with fluorouracil, floxuridine, and topoisomerase 1 poisons. Mol Cancer Ther 2010;9:3105-14.
48. Pardee TS, Stadelman K, Jennings-Gee J, Caudell DL, Gmeiner WH. The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells. Oncotarget 2014;5:4170-9.
49. Holbeck SL, Collins JM, Doroshow JH. Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines. Mol Cancer Ther 2010;9:1451-60.
50. Gmeiner WH, Yu S, Pon RT, Pourquier P, Pommier Y. Structural basis for topoisomerase I inhibition by nucleoside analogs. Nucleosides Nucleotides Nucleic Acids 2003;22:653-8.
51. Gmeiner WH, Salsbury F Jr, Olsen CM, Marky LA. The stability of a model substrate for topoisomerase 1-mediated DNA religation depends on the presence of mismatched base pairs. J Nucleic Acids 2011;2011:631372.
52. Jennings-Gee J, Pardee TS, Gmeiner WH. Replication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activity. Exp Hematol 2013;41:180-8.e4.
53. Gmeiner WH, Gearhart PJ, Pommier Y, Nakamura J. F10 cytotoxicity via topoisomerase I cleavage complex repair consistent with a unique mechanism for thymineless death. Future Oncol 2016;12:2183-8.
54. Das BB, Huang SY, Murai J, Rehman I, Ame JC, et al. PARP1-TDP1 coupling for the repair of topoisomerase I-induced DNA damage. Nucleic Acids Res 2014;42:4435-49.
55. Pardee TS, Gomes E, Jennings-Gee J, Caudell D, Gmeiner WH. Unique dual targeting of thymidylate synthase and topoisomerase1 by FdUMP[10] results in high efficacy against AML and low toxicity. Blood 2012;119:3561-70.
56. Gmeiner WH, Willingham MC, Bourland JD, Hatcher HC, Smith TL, et al. F10 inhibits growth of PC3 xenografts and enhances the effects of radiation therapy. J Clin Oncol Res 2014;2:pii:1028.
57. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, et al. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol 2014;116:447-54.
58. Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, et al. A phase I clinical trial of the Poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors. Clin Cancer Res 2018;24:744-52.
